ACCC is seeking to fill open positions on its Governmental Affairs Committee. The Committee monitors federal and state legislation and advises the Board of Trustees and the membership on matters that will impact reimbursement and access in community cancer care. The Committee recommends ways that ACCC can be most effective in influencing the executive and legislative branches of federal and state governments consistent with ACCC’s core purpose and strategic objectives. In addition to policymakers in Congress and the Centers for Medicare & Medicaid Services, the Committee works to establish relationships and maintain communication with federal agencies, independent organizations, and fellow stakeholders to advocate for the needs of the nation’s cancer patients as perceived by the leadership of community cancer programs.

In a recent article from Oncology Issues, authors conducted a systematic literature review and found that two main drivers of care disparities exist for transgender and nonbinary individuals with cancer: rigid binary gender frameworks and gaps in mental health care.

2026 ACCC Innovator Award Winner St. Luke's Cancer Institute noticed a significant administrative burden being placed on providers to review medical necessity validation for complex oncology therapies. To address the resulting rise in peer-to-peer requirements, delays in care, and pre-service denials, the team designed and implemented a new Clinical Documentation Integrity Registered Nurse role.

ACCC launched its Precision Medicine Stewardship Program to highlight institutions that have successfully built the infrastructure, workflows, and leadership models needed to deliver precision medicine at scale. TriHealth Cancer and Blood Institute in Cincinnati, Ohio, offers a compelling example of what it takes to move from aspiration to execution.

Although patients with relapsed or refractory multiple myeloma now have more treatment options than ever, their journeys are often complex. As clinicians consider when to introduce newer therapies such as bispecific antibodies, they must account for prior treatments, treatment-related toxicities, and comorbidities that may impact treatment decisions.
